ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Takeda, Arrowhead enter $1 billion agreement to develop RNAi treatment

by Megha Satyanarayana
October 17, 2020 | APPEARED IN VOLUME 98, ISSUE 40

 

Takeda Pharmaceutical and Arrowhead Pharmaceuticals will codevelop ARO-AAT, an Arrowhead RNA interference therapy for alpha-1 antitrypsin-associated liver disease. Arrowhead will receive $300 million up front, with subsequent payments totaling up to $740 million. Takeda will receive an exclusive license to commercialize the treatment outside the US, and the companies will develop it together in the US. There are no approved therapies for the disease, and it often leads to liver transplants.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment